BLA 761035 · Bristol Myers Squibb
Empliciti
Elotuzumab · Injection · SLAMF7-directed Immunostimulatory Antibody
NovelBreakthrough therapyPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 22, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 30, 2015
Approved uses
5
Original approval plus efficacy supplements
Registered trials
67
16 Phase 3, 7 recruiting
FAERS reports
5,171
4,210 serious, 920 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 22, 2022 Supplement 15 · Efficacy OrphanLetterLabel
- Oct 28, 2019 Supplement 10 · Efficacy OrphanLabelLetter
- Nov 6, 2018 Supplement 8 · Efficacy · priority review OrphanLabelLetter
- May 11, 2017 Supplement 5 · Efficacy OrphanLetterLabel
- Nov 30, 2015 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelReviewLetter
2 products under this application
- EMPLICITI · ELOTUZUMAB 400MG · INJECTABLE, INJECTION · Prescription
- EMPLICITI · ELOTUZUMAB 300MG · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elotuzumab" as an intervention, any sponsor and status, largest first.
- A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and LenalidomidePivotal-lookingActive, not recruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06208150 · 838 participants · Start Jan 22, 2024 · Primary completion Apr 1, 2026
Drug: Talquetamab; Pomalidomide and 4 more · For: Multiple Myeloma
Sites: Clovis, California; Santa Monica, California; New Haven, Connecticut · 242 sites in all
- Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple MyelomaPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01335399 · 748 participants · Start Aug 4, 2011 · Primary completion Oct 1, 2019
Drug: Lenalidomide; Dexamethasone and 5 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Mobile, Alabama; Chandler, Arizona · 235 sites in all
- Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple MyelomaPivotal-lookingCompleted
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT01239797 · 646 participants · Start Jun 20, 2011 · Primary completion Sep 2, 2014
Drug: Lenalidomide; Dexamethasone and 3 more · For: Lymphoma; Multiple Myeloma
Sites: Muscle Shoals, Alabama; Tucson, Arizona; Berkeley, California · 216 sites in all
- Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MMPivotal-lookingActive, not recruiting
Wuerzburg University HospitalAcademic, hospital or other
NCT03948035 · 576 participants (planned) · Start Aug 28, 2018 · Primary completion Aug 2029
Drug: Elotuzumab; Carfilzomib and 2 more · For: Newly Diagnosed Multiple Myeloma
Sites: Krems, Austria; Sankt Pölten, Austria; Graz, Austria · 56 sites in all
- A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed MyelomaPivotal-lookingCompleted
University of Heidelberg Medical CenterAcademic, hospital or other
NCT02495922 · 564 participants · Start Jun 2015 · Primary completion Jun 24, 2021
Drug: elotuzumab; Lenalidomide and 2 more · For: Multiple Myeloma
Sites: Aschaffenburg, Germany; Baden-Baden, Germany; Berlin, Germany · 68 sites in all
PfizerPfizer (PFE)
NCT06152575 · 492 participants (planned) · Start Feb 8, 2024 · Primary completion Aug 26, 2026
Drug: Elranatamab; Elotuzumab and 4 more · For: Multiple Myeloma
Sites: Mobile, Alabama; Beverly Hills, California; Clovis, California · 268 sites in all
- Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
CellCentric Ltd.Industry
NCT07772024 · 450 participants (planned) · Start Aug 2026 · Primary completion Nov 2029
Drug: InoPd; Investigator's choice of SAT · For: Multiple Myeloma Refractory; Multiple Myeloma in Relapse
Sites: Miami, Florida
CelgeneBristol Myers Squibb (BMY)
NCT03989414 · 424 participants (planned) · Start Sep 30, 2019 · Primary completion Nov 30, 2026
Drug: CC-92480; Bortezomib and 6 more · For: Multiple Myeloma
Sites: Denver, Colorado; Tampa, Florida; Atlanta, Georgia · 49 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Empliciti (Elotuzumab)
2024 spending
$2.2M
Beneficiaries
27
217 claims
Per beneficiary
$80,387
$2,644.77 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,844,301 |
| 2021 | $4,863,250 |
| 2022 | $3,001,928 |
| 2023 | $2,224,804 |
| 2024 | $2,170,460 |
Part B: Empliciti (Elotuzumab) · HCPCS J9176
2024 spending
$83.0M
Beneficiaries
1,050
9,908 claims
Per beneficiary
$79,064
2024 ASP limit $7.48 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $110,037,845 |
| 2021 | $97,730,346 |
| 2022 | $98,425,826 |
| 2023 | $89,425,920 |
| 2024 | $83,017,614 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial.
Dimopoulos MA, Dytfeld D, Grosicki S, et al. · J Clin Oncol 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
Jagannath S, Laubach J, Wong E, et al. · Br J Haematol 2018 · Clinical Trial, Phase II, Multicenter Study
- Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Parrondo RD, LaPlant BR, Elliott J, et al. · Blood Cancer J 2024 · Clinical Trial, Phase II, Letter
- Risk of adverse events in elotuzumab-treated patients with multiple myeloma: a systematic review and meta-analysis.
Yan Z, Dong H, Du Y, et al. · Ann Med 2026 · Systematic Review, Meta-Analysis
- Safety and efficacy of Elotuzumab combination therapy for patients with multiple myeloma: A systematic review and meta-analysis.
Noori M, Fayyaz F, Rezaei N · Expert Rev Anticancer Ther 2023 · Meta-Analysis, Systematic Review
- Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
Yee AJ, Laubach JP, Campagnaro EL, et al. · Blood Adv 2025 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Bristol Myers Squibb
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.